These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708 [TBL] [Abstract][Full Text] [Related]
9. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
11. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C Clin Transpl; 2009; ():433-8. PubMed ID: 20524311 [TBL] [Abstract][Full Text] [Related]
14. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
16. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment. Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA Clin Transpl; 2009; ():415-20. PubMed ID: 20524307 [TBL] [Abstract][Full Text] [Related]
18. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130 [TBL] [Abstract][Full Text] [Related]
19. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829 [TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]